title: [Pure red cell aplasia in patient affected by myelodysplastic syndrome treated with R-Epo].
abstract: Pure red cell aplasia (PRCA) is a rare condition described in patients with chronic kidney disease during alpha-Epo treatment subcutaneous administered generated by anti-R-Epo antibodies. Recently two cases of PRCA have been reported in patients affected by myelodysplastic syndrome treated with R-Epo. We described one more case of PRCA in a patient with refractory anemia treated with R-Epo.
authors.affiliation: UOA di Oncologia Medica, Regione Piemonte ASL VCO, Ospedale, Verbania.
authors.forename: Annalisa
authors.initials: A
authors.lastname: Luraschi
authors.forename: Sergio
authors.initials: S
authors.lastname: Montanara
authors.forename: Paola
authors.initials: P
authors.lastname: Fedeli
authors.forename: Paola
authors.initials: P
authors.lastname: Buscaglia
authors.forename: Ornella
authors.initials: O
authors.lastname: Fossati
authors.forename: Sergio
authors.initials: S
authors.lastname: Cozzi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Castello
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000368:Aged; D001803:Blood Transfusion; D004921:Erythropoietin / Q000009:adverse effects*; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000188:drug therapy; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D011994:Recombinant Proteins; D004921:Erythropoietin